Louisa Fleure speaks to ecancer about her experience as a nurse with the use of PARP inhibitors for the treatment of prostate cancer.

Louisa speaks about the relevant trials that the team at Guy's and St Thomas' NHS Trust are involved with and the support they provide to these patients.

She speaks about the anticipation around personalised medicine in this setting both for healthcare professionals and patients, and how the team are preparing for genetic counselling and genomic testing.

Louisa closes by talking about the feedback they have received from patients regarding PARP inhibitors and notes that they are generally well tolerated with manageable side effects.

This programme has been supported by an unrestricted educational grant from Pfizer.